Assembly Biosciences, Inc.
ASMB
Positions held
Your positionsASMB isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $464.63M | Enterprise value | $146.62M | Trailing P/E | 21.94 | Forward P/E | -8.87 |
| PEG | — | Price / book | 1.48 | Beta | 1.16 | Dividend yield | 0.00% |
| Revenue growth | 38.9% | Earnings growth | — | Gross margin | 15.0% | Operating margin | -47.4% |
| Profit margin | -0.1% | ROE | -0.0% | ROA | -2.7% | Debt / equity | 0.01 |
| Current ratio | 13.99 | Free cash flow | -$27.87M | Analyst recommendation | none | Mean target | $52.00 |
| 52w high | $39.71 | 52w low | $21.80 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $13.4M | $8.2M | $42.5M | $10.8M | $9.6M | — |
| Op margin | -47.4% | -138.4% | 46.6% | -100.9% | -115.2% | — |
| Net income | -$3.9M | -$9.1M | $22.1M | -$9.2M | -$10.2M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$6.3M | -$11.4M | $19.8M | -$10.9M | -$11.1M | — |
- Revenue +63% vs prior quarter ($13M vs $8.2M).
- Operating margin expanded to -47.4%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $72.3M | $28.5M | $7.2M | $0.0M | — |
| Op margin | -16.8% | -159.3% | -902.5% | — | — |
| Net income | -$6.1M | -$40.2M | -$61.2M | -$93.1M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$12.1M | -$45.4M | -$64.6M | -$94.1M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-05 · Assembly Biosciences Plans to Present Posters Featuring New Phase 1a Data From ABI-6250 Program
2026-09-17 · Best Momentum Stocks to Buy for September 17th
2026-09-17 · New Strong Buy Stocks for September 17th
2026-09-10 · Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference
2026-09-09 · Oil Surge Continues on Escalating Middle East Crisis: 4 Defensive Picks
2026-09-08 · Assembly Biosciences Exercises Option to Share US Costs, Profits for Herpes Program With Gilead
2026-09-08 · Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program
2026-09-08 · Zacks.com featured highlights include EuroDry, RCM, Assembly Biosciences, Delcath and National Energy Services
2026-09-07 · Wall Street Analysts See a 35.71% Upside in Assembly Biosciences (ASMB): Can the Stock Really Move This High?
2026-09-04 · Should You Buy Assembly Biosciences (ASMB) After Golden Cross?
2026-09-04 · 5 Stocks With Recent Price Strength Buoyed by a Strong August
Price (daily)
Full chart · RSI · MACD · patterns